Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, ...

Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical ...

According to TipRanks.com, Lebowitz is a 4-star analyst with an average return of 4.4% and a 55.7% success rate. Lebowitz covers the Healthcare sector, focusing on stocks such as Arrowhead ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.

On June 20, Madrigal Pharmaceuticals moved closer to introducing the first treatment for metabolic dysfunction-associated steatohepatitis/MASH in Europe.

QRG Capital Management Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund ...